Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cancer vaccines: limited success but the research should remain viable.
Baxevanis CN, Perez SA. Baxevanis CN, et al. Among authors: perez sa. Expert Rev Vaccines. 2016 Jun;15(6):677-80. doi: 10.1586/14760584.2016.1145057. Epub 2016 Feb 9. Expert Rev Vaccines. 2016. PMID: 26796430 No abstract available.
Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.
Gritzapis AD, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez SA, Baxevanis CN, Papamichail M. Gritzapis AD, et al. Among authors: perez sa. Br J Cancer. 2003 Apr 22;88(8):1292-300. doi: 10.1038/sj.bjc.6600888. Br J Cancer. 2003. PMID: 12698199 Free PMC article.
Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Baxevanis CN, et al. Among authors: perez sa. Cancer Immunol Immunother. 2006 Jan;55(1):85-95. doi: 10.1007/s00262-005-0692-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15948002 Review.
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN. Sotiriadou NN, et al. Among authors: perez sa. Cancer Immunol Immunother. 2007 May;56(5):601-13. doi: 10.1007/s00262-006-0213-z. Epub 2006 Sep 8. Cancer Immunol Immunother. 2007. PMID: 16960693
Increased frequency of CD4+ cells expressing CD161 in cancer patients.
Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. Iliopoulou EG, et al. Among authors: perez sa. Clin Cancer Res. 2006 Dec 1;12(23):6901-9. doi: 10.1158/1078-0432.CCR-06-0977. Clin Cancer Res. 2006. PMID: 17145807
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M. Perez SA, et al. Clin Cancer Res. 2007 May 1;13(9):2714-21. doi: 10.1158/1078-0432.CCR-06-2347. Clin Cancer Res. 2007. PMID: 17473204
Cancer immunotherapy: perspectives and prospects.
Perez SA, Papamichail M. Perez SA, et al. Adv Exp Med Biol. 2008;622:235-53. doi: 10.1007/978-0-387-68969-2_19. Adv Exp Med Biol. 2008. PMID: 18546632 Review. No abstract available.
Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN. Gritzapis AD, et al. J Immunol. 2008 Jul 1;181(1):146-54. doi: 10.4049/jimmunol.181.1.146. J Immunol. 2008. PMID: 18566379
Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN, Perez SA, Papamichail M. Baxevanis CN, et al. Among authors: perez sa. Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Cancer Immunol Immunother. 2009. PMID: 18704409 Review.
Cancer immunotherapy.
Baxevanis CN, Perez SA, Papamichail M. Baxevanis CN, et al. Among authors: perez sa. Crit Rev Clin Lab Sci. 2009;46(4):167-89. doi: 10.1080/10408360902937809. Crit Rev Clin Lab Sci. 2009. PMID: 19650714 Review.
116 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page